Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 
Daniel C.  Liebler

Daniel C. Liebler, Ph.D.

Director, Center in Molecular Toxicology
Director, Jim Ayers Institute for Precancer Detection and Diagnosis
Ingram Professor of Cancer Research
Professor of Biochemistry, Pharmacology, and Biomedical Informatics
Researcher

Contact Information:

Vanderbilt University Medical Center
465 21st Avenue South, U1213 MRB III
Nashville , TN 37232-6350
615-322-3063
Fax: 615-936-1001

Profile

Daniel C. Liebler is Ingram Professor of Cancer Research and Professor of Biochemistry, Pharmacology and Biomedical Informatics at the Vanderbilt University School of Medicine. After completing his doctoral training in pharmacology at Vanderbilt and postdoctoral training in biochemistry at Oregon State, he served on the faculty at the University of Arizona prior to joining the Department of Biochemistry and the Vanderbilt-Ingram Cancer Center in 2003.
Read more ....

Daniel C. Liebler is Ingram Professor of Cancer Research and Professor of Biochemistry, Pharmacology and Biomedical Informatics at the Vanderbilt University School of Medicine. After completing his doctoral training in pharmacology at Vanderbilt and postdoctoral training in biochemistry at Oregon State, he served on the faculty at the University of Arizona prior to joining the Department of Biochemistry and the Vanderbilt-Ingram Cancer Center in 2003. He is Director of the Jim Ayers Institute for Precancer Detection and Diagnosis at Vanderbilt, which is dedicated to the advancement of cancer diagnostics. He leads the Vanderbilt program in the National Cancer Institute-funded Clinical Proteomic Tumor Analysis Consortium (CPTAC) network, which is integrating proteomics with genomic technologies to understand the molecular drivers of cancer. Dr. Liebler is also the co-Director of the Vanderbilt Biomarker Developmental Laboratory in the NCI Early Detection Research Network. Dr. Liebler's research program has focused for over 25 years on toxicology, chemical biology and cancer biology, with an emphasis on application of mass spectrometry and proteomics.

Education
  • B.S. Chemistry, Villanova (1980)
  • Ph.D. Pharmacology, Vanderbilt (1984)
Research Specialty

Proteomic biomarkers for cancer detection and diagnosis; analysis and mechanisms of cell injury by reactive electrophiles

Research Description

Dr. Liebler’s research program addresses two broad problems that are linked by the application of analytical proteomics technologies, particularly mass spectrometry. The first problem is the development of protein biomarkers as diagnostics for early cancer detection and for guiding therapy of established disease. Application of standardized mass spectrometry-based proteomics technology platforms enables discovery and analytical validation of candidate biomarkers in human clinical specimens. Current work is directed at development of plasma-based diagnostics for early detection of colon and lung cancer and tumor tissue-based diagnostics for identifying high-risk cancers and predicting response to therapy.

The second problem is the role protein damage by reactive electrophiles in chemical toxicity and disease processes. This work involves development of methods to analyze modified and damaged proteins and to assess the impact of protein damage by reactive chemicals. Major areas of current focus are the characterization of global protein modification by endogenous lipid electrophiles in oxidative stress and the identification of signaling sensors targeted by electrophiles and the mechanisms by which chemical modification of these sensor proteins initiate stress responses.

Publications